Physician
Internal Medicine
Dr. Richard M. Weinshilboum, MD
|
|
Give Review
Richard M. Weinshilboum, MD is an expert in the field of Internal Medicine. He studied medicine at University of Kansas School of Medicine. He has 1 awards "Elected Member". Richard M. Weinshilboum, MD is also published. He has 88 publications published. The lastest publication: "TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.'
Publications
- TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
- Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
- KnowEnG: a knowledge engine for genomics.
- A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
- The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
- Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer.
- Treatment Outcomes of Depression: The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study.
- Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.
- Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations.
- Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.
- TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation.
- Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology.
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations.
- Genome-wide association studies in pharmacogenomics: successes and lessons.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- Mammographic breast density response to aromatase inhibition.
- FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
- Challenges in Implementing Genomic Medicine: The Mayo Clinic Center for Individualized Medicine.
- Interview: Richard M Weinshilboum talks to Hannah Branch, Assistant Commissioning Editor.
- Two-Phase Designs to Follow-Up Genome-Wide Association Signals With DNA Resequencing Studies.
- Implementing genomic medicine in the clinic: the future is here.
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
- Identification of a novel percent mammographic density locus at 12q24.
- Serine Hydroxymethyltransferase 1 and 2: Gene Sequence Variation and Functional Genomic Characterization.
- Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
- Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record.
- Methionine Adenosyltransferase 2A/2B and Methylation: Gene Sequence Variation and Functional Genomics.
- SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.
- Genomics and drug response.
- Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen.
- Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study.
- Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation.
- CYP2C19 variation and citalopram response.
- Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity.
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
- Thiopurine pathway.
- Coprescription of tamoxifen and medications that inhibit CYP2D6.
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
- Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.
- Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
- Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
- Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies.
- Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
- Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
- Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation.
- Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
- Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
- Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization.
- Glutathione s-transferase p1: gene sequence variation and functional genomic studies.
- Structural basis of substrate recognition in thiopurine s-methyltransferase.
- Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release.
- Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects.
- Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1.
- Metabolomics: a global biochemical approach to drug response and disease.
- Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics.
- Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics.
- Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
- A comprehensive examination of CYP19 variation and breast density.
- Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer.
- Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.
- Glutathione S-transferase omega 1 and omega 2 pharmacogenomics.
- Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review.
- Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics.
- Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies.
- Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
- Pharmacogenetics and pharmacogenomics: development, science, and translation.
- Human aromatase: gene resequencing and functional genomics.
- Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics.
- Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation.
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
- Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system.
- Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies.
- Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model.
- Thiopurine methyltransferase activity in red blood cells of dogs.
- Cat red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics.
- Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia.
- The genomic revolution and medicine.
- N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
- Catecholestrogen sulfation: possible role in carcinogenesis.
- The Gordon Wilson Lecture. The Mayo model: one path to an academic medical center.
- Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.
Schools
University of Kansas School of Medicine
Doctors Specialties
- Internal Medicine
Accepted Insurances
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
Awards
- Elected Member
Education
-
Massachusetts General Hospital -
University of Kansas School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Kalie Y. Kebed, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salma Iftikhar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renumathy Dhanasekaran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel D. Havyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis E. Ward, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Valerie J. Rader, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie A. Bjoraker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shivani N. Desai, MD |
|
|
Dr. Paul S. Mueller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ivo C. Ditah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Jonathan D. Potter, OT
This Doctor is OpenDoctor Recommended.
|
|
|
Yogesh N. Reddy |